Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer.

Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Dec;163(4):285-292 Authors: Kolarova I, Vanasek J, Odrazka K, Melichar B, Ryska A, Petera J, Vosmik M, Dolezel M Abstract Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological properties and affects the selection of therapies. On the basis of molecular genetics, four principal subtypes, including luminal A, luminal B, HER2-enriched (HER-2-E), and basal-like can be distinguished. Breast tumors characterized by HER-2 positivity and simultaneous expression of hormone receptors, triple positive breast cancers (TPBC) are of increasing interest owing to the unique biological characteristics associated with complex interactions between HER-2 and hormone receptor signaling pathways. Interactions between hormone receptors and HER-2 explain the decreased efficacy of hormonal therapy in comparison with HER-2-negative patients. The expression of estrogen receptors in HER-2 positive tumors may also be associated with resistance to anti-HER-2 treatment. Multiple available therapeutic options, including hormonal therapy, anti-HER-2 agents and cytotoxic drugs explain favorable prognosis of TPBC. Escalation and de-escalation therap...
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research

Related Links:

Condition:   Invasive Breast Cancer Interventions:   Drug: Cemiplimab;   Drug: Paclitaxel;   Drug: Carboplatin (not mandatory);   Drug: Doxorubicin;   Drug: Cyclophosphamide Sponsor:   Medical College of Wisconsin Not yet recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSION: The IL-10 gene rs1800872 polymorphism was associated with BC susceptibility in this sample from the Mexican population. PMID: 31983108 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
This study aimed to validate whether the recently-proposed prognostic grading system, initial brain metastasis velocity (iBMV), is applicable to breast cancer patients receiving stereotactic radiosurgery (SRS). We focused particularly on whether this grading system is useful for patients with all molecular types, i.e., positive versus negative for EsR, PgR and HER2.Methods and materialsThis was an institutional review board-approved, retrospective cohort study using our database, prospectively accumulated at three gamma knife institutes, during the 20-year-period since 1998. We excluded patients for whom the day of primary...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, HER2 targeted therapies have significantly improved survival.1,2 However, the cardiotoxicity associated with these therapies limits its use in some patients.3 In the metastatic setting HER2 targeted therapies are used until disease progression or toxicity.4,5 Although prolonged trastuzumab therapy may be associated with a higher risk of cardiotoxicity, this is felt to be counterbalanced by survival benefits of HER2 targeted therapy.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 25 January 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Mirza Muhammad Faran Ashraf Baig, Wing-Fu Lai, Reyaj Mikrani, Mehreen Jabeen, Muhammad Naveed, Muhammad Abbas, Muhammad Asim Farooq, Anam Ahsan, Said Abasse Kassim, Ghulam Jilany Khan, Muhammad Tayyab AnsariAbstractDNA based nano-carriers synthesized from short circular scaffolds (circular DNA nanotechnology) attains stiffer topology for ligand functionalization (neuregulin-1/NRG-1 ligand) and biological applications (targeted drug delivery). Daunorubicin (DR) is a hydrophobic chemical that requires robust ...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Authors: Kang YJ, Lee HB, Kim YG, Han J, Kim Y, Yoo TK, Lee ES, Moon HG, Noh DY, Han W Abstract Objective: While the value of Ki-67 has been recognized in breast cancer, controversy also exists. The goal of this study is to show the prognostic value of Ki-67 according to progesterone receptor (PgR) expression in patients who have estrogen receptor- (ER-) positive, human epidermal growth factor receptor 2- (HER2-) negative early breast cancer. Methods: The records of nonmetastatic invasive breast cancer patients who underwent surgery at a single institution between 2009 and 2012 were reviewed. Primary end point ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
CONCLUSION: Patients with amplification of CEP17 had a co-amplified HER2 and were more commonly HER2+, LN positive and grade 3 in the nuclear component of grade. PMID: 31977265 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Jie Yi, Liwen Ren, Dandan Li, Jie Wu, Wan Li, Guanhua Du, Jinhua WangAbstractBreast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue. The aim of this study was to investigate the function of TFF1 in BCs, and to assess whether serum TFF1 could be used in for...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 23 January 2020Source: Cancer CellAuthor(s): Dhivya R. Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung-min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J. Wick, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan AuerbachSummaryWe developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance ...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Current imaging methods that are used to spot tumors don’t provide much information about the rate of activity of the cells making up the diseased tissues. Breast cancer tumors, for example, are mostly classified into a few categories based on ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Materials Medicine Oncology Radiology Source Type: blogs
More News: Biomedical Science | Breast Cancer | Cancer | Cancer & Oncology | Czechia Health | Genetics | HER2 | Hormonal Therapy | Hormones | Immunotherapy | Molecular Biology | Neoadjuvant Therapy | Toxicology